Viking Therapeutics (VKTX) Non Operating Investment Income (2024 - 2026)

Viking Therapeutics has reported Non Operating Investment Income for 3 years, with the latest figure at $30000.0 in Q2 2026.

• Quarterly Non Operating Investment Income rose 650.0% year-over-year to $30000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $144000.0 (up 24.14% YoY) and the FY2025 annual result came in at $55000.0, down 50.89% from the prior year.
• Non Operating Investment Income grew to $30000.0 in Q2 2026 per VKTX's latest filing, from $4000.0 in the prior quarter.
• Over five years, Non Operating Investment Income peaked at $109000.0 in Q3 2024 and troughed at $1000.0 in Q4 2024.
• A 3-year average of $29200.0 and a median of $4000.0 in 2025 frame the typical range for Non Operating Investment Income.
• The sharpest annual moves came in 2025 and 2026: Non Operating Investment Income jumped 100.0% in 2025, then soared 650.0% in 2026.
• Over 3 years, Non Operating Investment Income stood at $1000.0 in 2024, then jumped by 300.0% to $4000.0 in 2025, then jumped by 650.0% to $30000.0 in 2026.
• According to Business Quant data, Non Operating Investment Income over the past three periods registered $30000.0, $4000.0, and $1000.0 for Q2 2026, Q2 2025, and Q4 2024 respectively.